CYCC · Cyclacel Pharmaceuticals Inc

-

Please sign in to comment on CYCC

1 Comment

Admin

4 years, 1 month ago

Cyclacel Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 12.2% below its 200 day moving average.

From a valuation standpoint, the stock is 94.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 74.6.

Cyclacel Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 21.6% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 6.6% to $-1M since the same quarter in the previous year.

Based on the above factors, Cyclacel Pharmaceuticals, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US23254L6039

Market Cap	63M
PE Ratio	None
Target Price	1
Dividend Yield	0.0%
Beta	0.15

ABOUT

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

CYCC · Cyclacel Pharmaceuticals Inc

-

Cyclacel Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Cyclacel Pharmaceuticals Inc using a moving average strategy